{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-225456","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2022-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.099273+00:00","generated_at":"2026-06-23T22:27:53.557850+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Halozyme ups revolver to $575M, repays term loan and revolver with convertible note proceeds","bullets":["Revolving credit facility increased by $225M to $575M; all other terms unchanged.","Company repaid entire term loan facility and all outstanding revolver borrowings using proceeds from previously issued convertible notes.","Amendment included 11 increase lenders: Bank of America, Wells Fargo, JPMorgan, Citibank, Goldman Sachs, Mizuho, Silicon Valley Bank, and others.","Conditions included pro forma Consolidated Net Leverage Ratio not exceeding 0.25:1.00 less than the permitted level."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-225456","json":"https://secwatch.observer/filing/0001193125-22-225456.json","markdown":"https://secwatch.observer/filing/0001193125-22-225456.md","text":"https://secwatch.observer/filing/0001193125-22-225456.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000119312522225456/0001193125-22-225456-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000119312522225456/d384340d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T22:27:53.557850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}